• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Vaccinex Inc.

    3/27/25 8:24:58 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VCNX alert in real time by email
    15-12G 1 d906343d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38624

     

     

    Vaccinex, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    1895 Mount Hope Avenue

    Rochester, New York 14620

    (585) 271-2700

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 213

    Pursuant to the requirements of the Securities Exchange Act of 1934, Vaccinex, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        Vaccinex, Inc.
    Date: March 27, 2025     By:   /s/ Maurice Zauderer
          Maurice Zauderer
          Chief Executive Officer

     

     

     

    Get the next $VCNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease

    ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements provide that, in exchange

    12/23/25 8:01:00 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

    ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO)

    5/27/25 8:45:00 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

    Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne

    4/21/25 8:45:00 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VCNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Friedberg Albert bought $451 worth of shares (100 units at $4.51) (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    8/13/24 4:30:45 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Friedberg Albert bought $30,349 worth of shares (6,406 units at $4.74) (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    8/7/24 4:04:52 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Friedberg Albert bought $55,238 worth of shares (11,703 units at $4.72) (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    8/2/24 4:05:32 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VCNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Friedberg Albert was granted 30,756 shares (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    11/18/24 4:06:19 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Zauderer Maurice was granted 46,153 shares (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    11/18/24 4:05:50 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Zauderer Maurice exercised 113,650 shares at a strike of $5.64 (SEC Form 4)

    4 - VACCINEX, INC. (0001205922) (Issuer)

    9/20/24 4:14:02 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VCNX
    SEC Filings

    View All

    SEC Form 10-K filed by Vaccinex Inc.

    10-K - VACCINEX, INC. (0001205922) (Filer)

    4/15/25 5:12:41 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Vaccinex Inc.

    NT 10-K - VACCINEX, INC. (0001205922) (Filer)

    4/1/25 7:01:02 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Vaccinex Inc.

    15-12G - VACCINEX, INC. (0001205922) (Filer)

    3/27/25 8:24:58 AM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VCNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vaccinex Inc.

    SC 13G - VACCINEX, INC. (0001205922) (Subject)

    11/14/24 3:39:20 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    9/20/24 5:15:25 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care